ByteDance, the parent company of TikTok, is making a serious push into AI-driven drug discovery. The Chinese tech giant has completed a $290 million fundraising round for Anew Labs, its newly spun-off AI drugmaking unit headquartered in Shanghai. The spinoff was designed to give the unit more room to grow, as AI drug discovery operates under a fundamentally different business logic than ByteDance's core social media and internet operations.

The round drew a who's who of major investors, with HSG (formerly Sequoia China), IDG Capital, and Hillhouse Investment co-leading the raise. Strategic and state-backed investors also joined in, signaling both commercial and governmental confidence in the venture.

By the Numbers:

• $290M raised in Anew Labs' inaugural external funding round
• $1.5B post-money valuation achieved after the raise
• 56% stake retained by ByteDance following the spinoff
• Key investors include HSG, IDG Capital, Hillhouse Investment, 5Y Capital, Gaorong Ventures, Primavera Venture Partners, Boyu Capital, SBP Group, and the state-backed Shanghai Future Industries Fund

Why it matters: This deal signals growing momentum behind AI-powered drug discovery in China, with major venture capital and state-backed funds placing large bets on the sector. As global competition in AI-driven pharma heats up, Anew Labs' billion-dollar valuation out of the gate suggests investors see transformative potential in using AI to accelerate and de-risk the drug development pipeline.